Skip to main content
Figure 4 | Critical Care

Figure 4

From: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

Figure 4

Mortality by Acute Physiology and Chronic Health Evaluation II (APACHE II) score quartiles in clinical evaluation committee community-acquired pneumonia patients treated with tifacogin or placebo. The quartiles were determined by PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial results.

Back to article page

Critical Care

ISSN: 1364-8535